9 December 2023
Hogan Lovells advises EyePoint Pharmaceuticals on its $230 million follow-on public offering of common stock
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Steve Abrams Lead | Hogan Lovells Cadwalader | Partner | capital markets | Philadelphia |
| Stephen Nicolai Lead | Hogan Lovells Cadwalader | Partner | capital markets | Philadelphia |
| David Will | Hogan Lovells Cadwalader | Senior associate | capital markets | New York |
| Kayvon Paul | Hogan Lovells Cadwalader | Associate | capital markets | Philadelphia |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 230m (US$230 million)
- What the figure measures
- Issue size
- Client
- EyePoint Pharmaceuticals, Inc.Issuer
- Counterparties
- J.P. Morgan (Underwriters)
TD Cowen (Underwriters)
Guggenheim Securities (Underwriters)
Cantor (Underwriters)
Mizuho (Underwriters)
Laidlaw & Company (UK) Ltd. (Underwriters)